Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum

Verified siteinfo

Germany Hoelkeskampring 40, 44625 Herne, Germany

  • 7 trials recruiting
  • Acute myeloid leukaemia · Bladder cancer · Chronic lymphocytic leukaemia
  • Adult patients

About Specializations

Marien Hospital Herne Universitätsklinikum der Ruhr-Universität Bochum in Herne, Germany specialises in clinical trials of conditions such as Acute myeloid leukaemia, Bladder cancer, Chronic lymphocytic leukaemia, Pain, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology

The medical center is at the forefront of oncology research, with a particular focus on Muscle Invasive Bladder Cancer (MIBC). The institution is dedicated to advancing treatment options and improving patient outcomes through innovative clinical trials.

  • Perioperative therapies
  • Immunotherapy advancements
  • Comparative effectiveness of treatment regimens

By exploring the efficacy of novel combinations such as pembrolizumab and enfortumab vedotin against traditional chemotherapy, the center contributes significantly to the evolving landscape of cancer treatment.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Hoelkeskampring 4044625 HerneGermany
Open in maps ↗
Recruiting now
7 trials
Conditions studied
34
Partner status
Verified site

More sites in HerneGermany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

29 clinical trials

Chronic lymphocytic leukaemia+1

Recruiting

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Prostate cancer metastatic

Recruiting

Study of AZD5305 with Abiraterone Acetate and Darolutamide in Men with Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Neoplasm malignant+7

Recruiting

Study on the Safety and Effects of XL092 with Nivolumab, Ipilimumab, and Relatlimab for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ipilimumab
  • Sponsor:Exelixis Inc.

Bladder transitional cell carcinoma

Recruiting

Study Comparing Erdafitinib and Mitomycin for Patients with Intermediate-risk Non-muscle Invasive Bladder Cancer with FGFR Gene Alterations

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Erdafitinib
  • Sponsor:Janssen Cilag International

Herpes simplex+1

Recruiting

Study on the Effect of Acyclovir in ICU Patients with Pneumonia and Herpes Simplex Virus Type 1 Detected in Lung Fluid

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Aciclovir
  • Sponsor:Friedrich-Schiller-Universitaet Jena

Acute myeloid leukaemia

Recruiting

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Adenocarcinoma gastric+1

Recruiting

Study on the Effectiveness of Oxaliplatin, Docetaxel, and Fluorouracil in Patients with Resectable Gastric and Gastroesophageal Junction Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Krankenhaus Nordwest GmbH

Small intestine adenocarcinoma

Not yet recruiting

Randomized trial of irinotecan drug combination versus standard therapy as first-line treatment in patients with locally advanced or metastatic small bowel adenocarcinoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Charite Universitaetsmedizin Berlin KöR

Atrial fibrillation

Not yet recruiting

Colchicine after Electrocardioversion to Prevent Recurrence of Atrial Fibrillation in Adult Patients

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Universitaetsspital Basel

Hormone-dependent prostate cancer+3

Not yet recruiting

BMS-986365 in Metastatic Castration-Sensitive Prostate Cancer in Patients with Suboptimal PSA Response After ADT and ARPI

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BMS-986365
  • Sponsor:AIO-Studien gGmbH

Chronic kidney disease+1

Not recruiting

Study on Baxdrostat and Dapagliflozin for Adults with Chronic Kidney Disease and High Blood Pressure

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Baxdrostat
  • Sponsor:AstraZeneca AB

Chronic kidney disease

Not recruiting

Study of BI 690517 and empagliflozin combination for protection of heart and kidneys in patients with chronic kidney disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.